BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 18203319)

  • 1. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
    Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
    Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.
    Fujii H; Shimada Y; Hasegawa M; Takehara K; Sato S
    J Dermatol Sci; 2004 Jun; 35(1):43-51. PubMed ID: 15194146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
    Russo K; Hoch S; Dima C; Varga J; Teodorescu M
    J Rheumatol; 2000 Jan; 27(1):142-8. PubMed ID: 10648030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis.
    Kuwatsuka Y; Ogawa F; Iwata Y; Komura K; Muroi E; Hara T; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    Autoimmunity; 2009 Feb; 42(2):120-5. PubMed ID: 19021012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress.
    Iwata Y; Ogawa F; Komura K; Muroi E; Hara T; Shimizu K; Hasegawa M; Fujimoto M; Tomita Y; Sato S
    Rheumatology (Oxford); 2007 May; 46(5):790-5. PubMed ID: 17309887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M; Vidali M; De Andrea M; Azzimonti B; AirĂ² P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
    Nishijima C; Sato S; Takehara K
    J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
    Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
    Hayakawa I; Hasegawa M; Takehara K; Sato S
    Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis.
    Nishijima C; Hayakawa I; Matsushita T; Komura K; Hasegawa M; Takehara K; Sato S
    Clin Exp Immunol; 2004 Nov; 138(2):357-63. PubMed ID: 15498049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
    Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis.
    Hayakawa I; Hasegawa M; Matsushita T; Yanaba K; Kodera M; Komura K; Takehara K; Sato S
    Rheumatology (Oxford); 2005 Jul; 44(7):873-8. PubMed ID: 15797972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.
    Furuse S; Fujii H; Kaburagi Y; Fujimoto M; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2003 Jul; 30(7):1524-8. PubMed ID: 12858452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
    Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
    Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis.
    Hasegawa M; Sato S; Yanaba K; Komura K; Yamazaki M; Takehara K
    Ann Rheum Dis; 2004 Nov; 63(11):1514-7. PubMed ID: 15479907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
    Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
    J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.